```
11.AA_SEQUENCE 1.0

DG GGKA74_GNYSA PRELIMINARY; PRT; 633 AA.

AC GGKA74_GNYSA PRELIMINARY; PRT; 633 AA.

AC GGKA74_GNYSA

DG JUL-2004, sequence version 1.

DT 05-JUL-2004, sequence version 1.

DT 07-FEB-2006, antry version 9.

DE Ankyrian repeat protein-like.

ShamacoJ1112 GGG.34,

NAME-201112 GGG.34,

NAME-201112 GGG.34,

NAME SEQUENCE.

COPYTIGHTE ON TO TAM THE MEMBLY GENERAL SECTION 1.

DR ASSART T. Matsumoto T., Yamamoto K.;

Submitted (AUG-2001) to the EMBL/GenBank/DDBJ databases.

CC COPYTIGHTED by the UniProt Consortium, see http://www.uniprot.org/terms

CC COPYTIGHTED by the UniProt Consortium see http://www.uniprot.org/terms

CC COPYTIGHTED by the UniProt Consortium see http://www.uniprot.org/terms

CC COPYTIGHTED by the Uni
```

1 MEDASKYAHS PAHLAVVRRD HASLRRLVAG LPRLPRAGEV ATEEESIAGE 51 AVADAVSAAI DRRDVPRRET PLHLAVRLRD PVAADILMSA GADWSLQNAD

51 101 151 201

GWSALQEAVC TREDAIATII ARHYQPLAWA KWCRRLPRVL ASINRIRDFY MEISFHFESS VIPFIGRIAP SDTYRIWKRG AALRADMTLA GFDGFRIQRS DQTFLFLGDG ARPEDAGGKE LHPGSLIVLA HKDKEITDAL EGAGVQPTEA EVAHEVALMS KTNMYRPGID VTQAELVPHL NWRRQERTEA VGHWKAKVYD

251 301 351 401

MLAVLUTVKS RRVPGAMTDE ELFAMEGEEK NGRGTELDAE LDEVLTAEER
KQLDSALRMG NQEEFFEERC EEGDGGADHL DANGVAKDKK GWFGWGGKKG
TKNDEKPSKA NQGŞKDESGD LGKGKEKNSS KKKKGASSGD STKHESEYKK
GLRPVLWLTP DFPLKTDELI PLLDVLANKV KAVRRLKELL TTKLPPGTFP
VKIALPIVPT IRVIVTFTKF EELQPLDEFA TPPSSPTQFQ DAKGKESEGS
GSWYSWVRGG RGAQSSDSGD SRNWKDEVDP FQIPSDYTWV DANEKKRRMK

AKKAKNRRGS TRKQSSKSTS SEGGHPMMDG FEE

501 551 601

```
The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polymocleotide; a composition comprising comprising polypeptide encoding polymocleotide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal encoding polypeptide. The synthetic apolipoprotein-E mimicking polypeptide has the following activities antilipsemic.

Cardiant, vasotropic, antiateriosclerocic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, chimpanzee or orangutan); for treating coronary artery disease, and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein (UDL) or very low ULDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking mimicking polypeptide of the invention.
                                                                                                                                                                                      apolipoprotein-E mimicking polypeptide, antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease, dysbeterilipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         treating
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Synthetic apolipoprotein-E mimicking polypeptide useful for treatir coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.
                                                                                                                                               Synthetic apolipoprotein-E mimicking peptide, SEQ ID No B.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Datta G;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Claim 4; SEQ ID NO 8; 79pp; English.
               ADO34231 standard; peptide; 18 AA.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Anantharamiah GM, Garber DW,
                                                                                                                                                                                                                                                                                                                                                                                                                                                            13-NOV-2003; 2003WO-US036268
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       13-NOV-2002; 2002US-0425821P.
                                                                                                    (first entry)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   (UABR-) UAB RES FOUND.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       WPI; 2004-411629/38.
                                                                                                                                                                                                                                                                                                                                                                     WO2004043403-A2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Sequence 18 AA;
11AA_SEQUENCE 1.0
                                                                                                    12-AUG-2004
                                                                                                                                                                                                                                                                                                                                                                                                                 27-MAY-2004
                                                                                                                                                                                                                                                                                                                            Synthetic
                                                           AD034231
```

ADO34231 Length: 18 February 14, 2007 16:01 Type: P Check: 3010

```
GIRRFLGSIW RFIRAFYG
```

ADO34334 standard; peptide; 18 SEQUENCE 1.0

Ş

(first entry) 12-AUG-2004

AD034334;

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 111.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic.

WO2004043403-A2

27-MAY-2004

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P

(UABR-) UAB RES FOUND

Garber DW, Anantharamiah GM,

Datta G;

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 111; 79pp; English.

such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysbetalioproteinaemia or atherosclerosis, and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolioprotein-E mimicking polypeptide enhances binding of low-density lipoprotein (LDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking mimicking polypeptide of the invention. The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid ancoding the synthetic apolipoprotein-E mimicking polypeptide, a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polypeptide a composition comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide and activities: antilipaemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal antibution a mammal

Sequence 18 AA;

Check: 3037 February 14, 2007 16:01 Type: P Length: 18 AD034334

GFRRILGSFW RIFRAIYG

11AA_SEQUENCE 1.0 ID AD034354 standard, peptide, 18 AD034354;

12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 131

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

```
apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction, stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
                                                                                                                                                                                                                                                                                                                                                                                                                                   Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 150.
                                                                                                                                                                                                                                                                                                                                                                         !!AA_SEQUENCE 1.0
ID AD034373 standard; peptide; 14 AA.
XX
                                                                                                                                                                                                                                                                                                                                                                                                                     12-AUG-2004 (first entry)
                                                                                                                                                                                                                                                                                                                                                                  GLRRFLGSIW RFLRAFYG
                    WO2004043403-A2.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           WO2004043403-A2
                                                                                                                                                                                                                                                                                                                                       Sequence 18 AA;
                                   27-MAY-2004
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         27-MAY-2004
                                                                                                                                                                                                                                                                                                                                                                                                       AD034373;
XBXBXBXEXBXBXBXBXX
```

The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, condition animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and conditions antiplody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an encolonal antiplody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide has the following activities: antilippement; cardiant, vasotropic, antiareriosolerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide has the following activities: antilippement; cardiant, vasotropic, antiareriosolerotic, cerebroprotective, and antianginal for reducing serum cholesterol in subject (including a mammal cusful for reducing serum cholesterol in a subject (including a mammal cube as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, condependent or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking copyeptide enhances binding of low-density lipoprotein (UDL) or very low changity lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E commitcking polypeptide of the invention. Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence. Claim 4; SEQ ID NO 150; 79pp; English. 13-NOV-2003; 2003WO-US036268 13-NOV-2002; 2002US-0425821P WPI; 2004-411629/38. Anantharamiah GM, (UABR-) UAB RES Sequence 14 AA; The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and carrier; and the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and contagnal of the synthetic apolipoprotein is subject (including a mammal contagnal infarction or atherocalerosis, and correducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angian a the synthetic apolipoprotein-E mimicking collypeptide enhances binding of low-density lipoprotein (LDL) or very low channer, and collypeptide chances binding of low-density lipoprotein-E mimicking a winderior apolipoprotein-E Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence. ADO34354 Length: 18 February 14, 2007 16:01 Type: P Check: 3055 Datta G; mimicking polypeptide of the invention. Claim 4; SEQ ID NO 131; 79pp; English. Anantharamiah GM, Garber DW, 13-NOV-2003; 2003WO-US036268 13-NOV-2002; 2002US-0425821P (UABR-) UAB RES FOUND WPI; 2004-411629/38. Synthetic.

invention relates to a novel synthetic apolipoprotein-E mimicking

Datta G;

Garber DW,

FOUND

apolipoprotein-E mimicking polypeptide, antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; LDL; AD034373 Length: 14 February 14, 2007 16:01 Type: P Check: 8199 Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 159. !!AA_SEQUENCE 1.0 ID ADO34382 standard; peptide; 14 AA. 13-NOV-2002; 2002US-0425821P. 13-NOV-2003; 2003WO-US036268 12-AUG-2004 (first entry) (UABR-) UAB RES FOUND GIRRFYGSIW RIFR WO2004043403-A2. 27-MAY-2004. ADO34382; Synthetic

Datta G;

Anantharamiah GM, Garber DW,

AD034368; -

WPI; 2004-411629/38

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 159; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E minicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polymelectide; a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide is antilipaemic, cardiant, vasotropic, antiatreriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, chimpanzee or orangutan); for treating coronary artery disease, and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein-E mimicking coronary artery low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking polypeptide of the invention.

Sequence 14 AA;

Pebruary 14, 2007 16:01 Type: P Check: 8222 ADO34382 Length: 14

GIRRYFGSIW RFLR

!!AA_SEQUENCE 1.0 ID ADO34368 standard; peptide; 14 AA.

12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 145.

vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; oconnary artery disease; dysbeteripoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL. apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant;

WO2004043403-A2.

27-MAY-2004

13-NOV-2003; 2003WO-US036268

13-NOV-2002; 2002US-0425821P

(UABR-) UAB RES FOUND.

Datta G; Anantharamiah GM, Garber DW,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide, a wector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is cuseful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysbetalipoprotein-enamenal or attherosclerosis; and for reducing the risk of myccardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances bluding of low-density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E comminicking polypeptide of the invention. Claim 4; SEQ ID NO 145; 79pp; English. $\overset{\text{\tiny M}}{\times}\overset{\text{\tiny M}}{\overset{\tiny M}}\overset{\text{\tiny M}}{\times}\overset{\tiny M}}\overset{\text{\tiny M}}{\overset{\tiny M}}\overset{\text{\tiny$

Sequence 14 AA;

ADO34368 Length: 14 February 14, 2007 16:01 Type: P Check: 8268

GIRRFYGSLW RFLR

Ź

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 158.

apolipoprotein-E mimicking polypeptide, antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial terrotion; seroke, embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VDL.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 158; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E

the synthetic apolipoprotein-E minicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E minicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E minicking polypeptide. The synthetic apolipoprotein-E minicking polypeptide has the following activities antilipaemic, cardiant, vasorropic, antiateriosclerotic, cerebroprotective, and artiandinal. The synthetic apolipoprotein-E minicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysberalipoproteinemenia or atherosclerosis, and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E minicking polypeptide enhances binding of low-density lipoprotein (LDL) or very low ULD by a cell. This sequence represents a synthetic apolipoprotein-E minicking minicking polypeptide of the invention. Jow

Sequence 14 AA;

Type: P Check: 8183 February 14, 2007 16:01 ADO34381 Length: 14

GIRRYFGSIW RFIR

!!AA_SEQUENCE 1.0 ID ADO34391 standard; peptide; 14 AA.

AD034391;

12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 168.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic.

WO2004043403-A2.

27-MAY-2004

13-NOV-2003; 2003WO-US036268

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND.

Datta G; Anantharamiah GM, Garber DW,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 168; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide, a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polyproteide acomposition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and apolipoprotein-E mimicking polypeptide and a carrier; cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is

such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysbetalipoproteinaemia or atheroscalerosis, and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein (IDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking mimicking polypeptide of the invention. useful for reducing serum cholesterol in a subject (including a mammal

Sequence 14 AA;

AD034391 Length: 14 February 14, 2007 16:01 Type: P Check: 8199

GIRRFYGSIW RIFR

!!AA_SEQUENCE 1.0 ID AD034427 standard; peptide; 14 AA.

ADO34427;

12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 204.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic.

WO2004043403-A2

27-MAY-2004.

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P.

UABR-) UAB RES FOUND.

Anantharamiah GM,

Datta

Garber DW,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 204; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E minicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E minicking polypeptide, a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E minicking polypeptide encoding polymucleotide, a composition comprising the synthetic apolipoprotein-E minicking polypeptide encoding polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E capolipoprotein-E minicking polypeptide has the following activities: and initialized an activities and a carrier; and continual antibody that specifically binds to the synthetic apolipoprotein-E cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E minicking polypeptide is cusful for reducing serum cholasterol in a subject (including a mammal cuben as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, composatilipoproteinaemia or atherosclerosis; and for reducing the risk of myccardial.infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E minicking polypeptide enhances binding of low-density lipoprotein (LDL) or very low

density lipoprotein (VLDL) to a cell and enhances degradation of LDL oVLDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking polypeptide of the invention.

ö

Sequence 14 AA;

SXSSS

Type: P Check: 8180 February 14, 2007 16:01 Length: 14 AD034427

GIRRYFGSIW RIFR

SEQUENCE 1.0 ADO34225 standard; peptide; 18 ADO34225;

¥

(first entry) 12-AUG-2004

Synthetic apolipoprotein-E mimicking polypeptide related R18L peptide.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic

'note= "N-terminal acetyl" /note= "C-terminal amide" Location/Qualifiers Modified-site Modified-site

WO2004043403-A2

27-MAY-2004

13-NOV-2003; 2003WO-US036268

13-NOV-2002; 2002US-0425821P

(UABR-) UAB RES FOUND.

Datta G; Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 2; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E minicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E minicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E minicking polypeptide and a carrier; and the synthetic apolipoprotein-E minicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E composition to synthetic apolipoprotein-E composition in synthetic apolipoprotein-E composition in synthetic apolipoprotein-E composition in synthetic apolipoprotein-E coraciant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E minicking polypeptide is cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E minicking polypeptide is cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and cancing as mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, composition or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein (LDL) or very low density lipoprotein (LDL) or very low

VLDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking polypeptide of the invention. apolipoprotein-E mimicking polypeptide, antilipaemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia, atherosclerosis, myocardial infarction, stroke, embolus, angina, low-density lipoprotein; LDL, very low density lipoprotein; VLDL. Check: 3010 Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 113. Type: P February 14, 2007 16:01 !!AA_SEQUENCE 1.0 ID AD034336 standard; peptide; 18 AA. 12-AUG-2004 (first entry) GIRRFLGSIW RFIRAFYG ADO34225 Length: 18 Sequence 18 AA; ADO34336; SXSS

13-NOV-2003; 2003WO-US036268. 13-NOV-2002; 2002US-0425821P. (UABR-) UAB RES FOUND.

WO2004043403-A2.

Synthetic.

27-MAY-2004

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis WPI; 2004-411629/38.

ö

Datta

Garber DW,

Anantharamiah GM,

Claim 4; SEQ ID NO 113; 79pp; English

comprises an amino acid sequence.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid coolypeptide. The invention further comprises an isolated nucleic acid a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monochonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide as the following activities: and this polypeptide has the following activities: and indicking polypeptide is cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal confinement as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, confinement and also for treating angula or atherosclerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angula. The synthetic apolipoprotein-E mimicking content (LDL) to a cell and enhances degradation of LDL or very low content by a cell. This sequence represents a synthetic apolipoprotein-E

Sequence 18 AA;

ADO34336 Length: 18 February 14, 2007 16:01 Type: P Check: 3007

GIRRFLGSIW RIFRAFYG

Wed Feb 14 16:03:30 2007

1!AA_SEQUENCE 1.0 ID ADO34338 standard; peptide; 18 AA. ADO34338;

(first entry) 12-AUG-2004

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 115.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; anginar: low-density lipoprotein; LDL; very low density lipoprotein; UDL;

Synthetic

WO2004043403-A2.

27-MAY-2004

13-NOV-2003; 2003WO-US036268

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND

ö Datta Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treatir coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 115; 79pp; English.

polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polypeptide; a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and common antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E cardiant, vasotropic, antiatreriosclerotic, cerebroprotective, and cantianginal. The synthetic apolipoprotein E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal confinemance or caragutan); for treating coronary artery disease, chimpanzee or caragutan); for treating coronary artery disease, dysbetalipoproteinaemia or atherosclerosis, and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; midicking polypeptide enhances binding of low-density lipoprotein. (UDD) or very low density lipoprotein. (VDDL) by a cell This sequence represents a synthetic apolipoprotein-E mimicking a synthetic apolipoprotein-E invention relates to a novel synthetic apolipoprotein-E mimicking the invention. mimicking polypeptide of

Sequence 18 AA;

Check: 2998 Type: P February 14, 2007 16:01 ADO34338 Length: 18

GLRRFIGSIW RFIRAFYG

ADO34341;

(first entry) 12-AUG-2004 Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 118.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; LDL;

Synthetic

WO2004043403-A2

27-MAY-2004

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND.

Datta G; Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 118; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic abolipoprotein-E mimicking polypeptide and a carrier; and the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E cardiant, vasotropic, antiatreriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E cardiant, vasotropic, antiatreriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysbetalipoproteinamia or attherosclerosis; and for reducing the risk of myocardial infarction or attroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein (LDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or cell and enhances degra mimicking polypeptide of the invention.

Sequence 18 AA;

February 14, 2007 16:01 Type: P Check: 3028 ADO34341 Length: 18

GIRRFLGSFW RIFRAIYG

!!AA SEQUENCE 1.0 ID ADO34352 standard; peptide; 18

Š

ADO34352;

(first entry) 12-AUG-2004

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 129.

apolipoprotein-E mimicking polypeptide, antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;

```
The invention relates to a novel synthetic apolipoprotein-E minicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E minicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E minicking polypeptide encoding polymucleotide; a composition comprising the synthetic apolipoprotein-E minicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E minicking polypeptide has the following activities: antilipaemic, and antianginal. The synthetic apolipoprocein-E minicking polypeptide is unclanding a manual setul for reducing serum cholesterolic, cerebroprocective, and artianginal. The synthetic apolipoprocein-E minicking polypeptide is such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, app. chimpanzee or orangutan); for treating coronary artery disease, chimpanzee or orangutan); for treating coronary artery disease, chimpanzee or orangutan); for treating coronary artery disease, and also for treating angina. The synthetic apolipoprotein-E minicking polypeptide enhances binding of low-density lipoprotein-E minicking polypeptide enhances binding of low-density lipoprotein (ULDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of the invention.
                                                                                                                                                                                                                                                                                                                                                                                                                  Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.
atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
                                                                                                                                                                                                                                                                                                                                 Datta G;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Claim 4; SEQ ID NO 129; 79pp; English.
                                                                                                                                                                                                                                                                                                                                 Garber DW,
                                                                                                                                                                                             13-NOV-2003; 2003WO-US036268.
                                                                                                                                                                                                                                         13-NOV-2002; 2002US-0425821P.
                                                                                                                                                                                                                                                                                     (UABR-) UAB RES FOUND
                                                                                                                                                                                                                                                                                                                                                                          WPI; 2004-411629/38.
                                                                                                                                                                                                                                                                                                                              Anantharamiah GM,
                                                                                                       WO2004043403-A2.
                                                                                                                                                 27-MAY-2004
                                                              Synthetic
```

Sequence 18 AA;

ADO34352 Length: 18 February 14, 2007 16:01 Type: P Check: 3076

GIRRFLGSLW RFLRAFYG

!!AA_SEQUENCE 1.0 ID ADO34379 standard; peptide; 14 AA.

ADO34379;

12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 156.

apolipoprotein-E mimicking polypeptide, antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol, coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

WO2004043403-A2

```
The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide and a carrier; and and ardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and cardiant, rabbit, cow, sheep, pig, human, monkey, ape, useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject, or and also for treating angina. The synthetic apolipoprotein [LDL] or very low density lipoprotein (VDL) to a cell and enhances degradation of LDL or cell and enhances binding of low-density lipoprotein-E mimicking view of the control or stroke; for a synthetic apolipoprotein-E
                                                                                                                                                                                                                                                     Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           apolipoprotein-E mimicking polypeptide, antilipaemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective; antianginal, serum cholesterol, coronary artery disease, dysbetalipoproteinnemia, atherosclerosis, myocardial infarction, stroke, embolus, angina, low-density lipoprotein, LDL, very low density lipoprotein; VLDL.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ADO34379 Length: 14 February 14, 2007 16:01 Type: P Check: 8208
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 157.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      mimicking polypeptide of the invention.
                                                                                                                                                                 Datta G;
                                                                                                                                                                                                                                                                                                                                              Claim 4; SEQ ID NO 156; 79pp; English.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   !!AA_SEQUENCE 1.0
ID ADO34380 standard; peptide; 14 AA.
                                                                                                                                                                   Ğ.
                                      13-NOV-2003; 2003WO-US036268,
                                                                               13-NOV-2002; 2002US-0425821P.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   13-NOV-2003; 2003WO-US036268.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               13-NOV-2002; 2002US-0425821P.
                                                                                                                                                                   Garber
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         12-AUG-2004 (first entry)
                                                                                                                        (UABR-) UAB RES FOUND
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        (UABR-) UAB RES FOUND
                                                                                                                                                                                                            WPI; 2004-411629/38.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          GLRRFYGSIW RFIR
                                                                                                                                                                   Anantharamiah GM,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               WO2004043403-A2.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sequence 14 AA;
27-MAY-2004
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        27-MAY-2004.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Synthetic.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ADO34380;
```

ö

Datta

Garber DW,

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence. Claim 4; SEQ ID NO 157; 79pp; English. Anantharamiah GM,

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transpenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide and activities; antilipaemic, cardiant, vasctropic, antiarteriosolecrotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal

chimpanzee or orangutan); for treating coronary artery disease, chimpanzee or orangutan); for treating coronary artery disease, dysbetaliapproteinsemia or atherosclerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject, and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein (UDL) or very low UDL by a call. This sequence represents a synthetic apolipoprotein of LDL or winding chimpantial contains a synthetic apolipoprotein-E mimicking mimicking polypeptide of the invention.

10%

Sequence 14 AA;

February 14, 2007 16:01 Type: P Check: 8229 ADO34380 Length: 14

GIRRFYGSLW RFIR

!!AA_SEQUENCE 1.0 ID ADO34383 standard; peptide; 14 AA.

AD034383;

12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 160.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vascuropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbeteralipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic.

WO2004043403-A2

27-MAY-2004

13-NOV-2003; 2003WO-US036268

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND

Datta G; Anantharamiah GM, Garber DW,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis PAY SERVE SE

Claim 4; SEQ ID NO 160; 79pp; English. comprises an amino acid sequence.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid composition the synthetic apolipoprotein-E mimicking polypeptide; a vector; a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and can monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E cardiant, vasotropic, antiaterios/alerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is cardiant, vasotropic, antiaterios/alerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, applyential partial poprotein or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein (VLDE) to a cell and enhances degradation of LDL or very low consisty lipoprotein (VLDE) to a cell and enhances degradation of LDL or cut mimicking polypeptide of the invention. $\mathbb{R} \times \mathbb{Q} \times \mathbb{Q} \cup \mathbb{Q} \cup$

Sequence 14 AA;

ADO34383 Length: 14 February 14, 2007 16:01 Type: P Check: 8210

GIRRYFGSLW RFIR

| IAA_SEQUENCE 1.0 | ID ADO34390 standard; peptide; 14 AA.

ADO34390;

12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 167.

apolipoprotein-E mimicking polypeptide, antilipaemic, cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary arrery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic.

WO2004043403-A2

27-MAY-2004.

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P

(UABR-) UAB RES FOUND.

ö Datta Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 167; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,

თ

(including animal or plant) control as transported, mountain abudget minimal or plant) comprising the synthetic apolipoprotein-E minicking polypeptide and acarier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E minicking polypeptide and acarier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E minicking polypeptide and acarier; and minicking polypeptide and acarier; and minicking polypeptide has the following activities: antilipaemic, cardiant, vasotropic, antiarerizosclerotic, cerebroprotective, and minicking polypeptide apolipoprotein-E minicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal, such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, the such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimparzee or orangutan); for treating coronary artery disease, dysbetalipoprotein-end or atherosclerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; on a lange for treating angina. The synthetic apolipoprotein-E minicking polypeptide enhances binding of low-density lipoprotein. [LDL) or very low density lipoprotein (LDL) to a cell and enhances degradation of LDL or minicking holyperties of the invarience represents a synthetic apolipoprotein-E minicking and proportein-E minicking mimicking polypeptide of the invention.

Sequence 14 AA;

February 14, 2007 16:01 Type: P Check: 8226 ADO34390 Length: 14

GFRRLYGSIW RFIR

!!AA_SEQUENCE 1.0 ID ADO34228 standard; peptide; 18 AA.

ADO34228;

(first entry) 12-AUG-2004

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 5.

apolipoprotein-E mimicking polypeptide, antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholestron; coronary artery disease; dysbetalipoproceinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic.

WO2004043403-A2.

27-MAY-2004

13-NOV-2003; 2003WO-US036268

13-NOV-2002; 2002US-0425821P

(UABR-) UAB RES FOUND.

Datta Anantharamiah GM, Garber DW,

Ö

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 5; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polymucleotide; a composition comprising mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide has the following activities: antilipaemic,

cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E minicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysbetalioproteinaemia or atherosclerosis, and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject, and also for treating angina. The synthetic apolipoprotein-E minicking polypeptide enhances binding of low-density lipoprotein (LDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or WLDL by a cell. This sequence represents a synthetic apolipoprotein-E minicking polypeptide of the invention.

\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$

Sequence 18 AA;

ADO34228 Length: 18 February 14, 2007 16:01 Type: P

GIRRFLGSIW RFIRAFYG

!!AA_SEQUENCE 1.0 ID AD034236 standard; peptide; 18 AA.

ADO34236;

12-AUG-2004 (first entry)

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; LDL; Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 13.

Synthetic.

WO2004043403-A2.

27-MAY-2004.

13-NOV-2003; 2003WO-US036268

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND.

Datta G; Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 13; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide has the following activities; antilipaemic, and antianginal. The synthetic apolipoprotein-E cardiant, vasotropic, antiateriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholescerol in a subject (including a mammal useful for reducing serum cholescerol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease dysecting or atherosclerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject;

mimicking 8866688

and also for treating angina. The synthetic apolipoprotein-E mimicking by Delypeptide enhances binding of low-density lipoprotein (ULD) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E polypeptide of the invention.

Sequence 18 AA;

February 14, 2007 16:01 Type: P Check: 3010 ADO34236 Length: 18

GIRRFLGSIW RFIRAFYG

!!AA_SEQUENCE 1.0 ID ADO34340 standard; peptide; 18 AA.

ADO34340;

(first entry) 12-AUG-2004

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 117.

apolipoprotein-E mimicking polypeptide, antilipaemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, antianginal, serum cholesterol, coronary artery disease, dysbetalipoproteinaemia, atherosclerosis, myocardial infarction, stroke, embolus, angina, low-density lipoprotein; LDL, very low density lipoprotein; VLDL.

Synthetic.

WO2004043403-A2

27-MAY-2004

13-NOV-2003; 2003WO-US036268

13-NOV-2002; 2002US-0425821P

(UABR-) UAB RES FOUND

Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Datta G;

Synthetic apolipoprotein-E mimicking polypeptide useful for treatir coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 117; 79pp; English.

Š cardiant, vasotropic, antiarreriosclerofic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E minicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; polypeptide enhances binding of low-density lipoprotein (IDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL, by a cell. This sequence represents a synthetic apolipoprotein-E The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transpensio, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polymucleotide; a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide of the invention.

Sequence 18 AA;

Check: 3031 Type: P February 14, 2007 16:01 Length: 18 ADO34340

GIRRFIGSIW RFLRAFYG

!!AA_SEQUENCE 1.0 ID AD034356 standard; peptide; 14

Ź

ADO34356;

(first entry) 12-AUG-2004 Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 133.

vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL. apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant;

Synthetic.

WO2004043403-A2.

27-MAY-2004

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND

Datta G; Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 133; 79pp; English.

such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject, and also for treating angina. The synthetic apolipoprotein [DLD or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein. The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide an composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal mimicking polypeptide of the invention.

Sequence 14 AA;

Type: P Check: 8202 February 14, 2007 16:01 Length: 14 ADO34356

GIRRFYGSIW RFIR

!!AA_SEQUENCE 1.0 ID AD034364 standard; peptide; 14 AA.

a

```
ADO34364;
```

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 141. (first entry) 12-AUG-2004

apolipoprotein-E mimicking polypeptide, antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL. Synthetic.

WO2004043403-A2.

27-MAY-2004

13-NOV-2003; 2003WO-US036268

13-NOV-2002; 2002US-0425821P

(UABR-) UAB RES FOUND

Anantharamiah GM, Garber DW,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 141; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polywoleletide; a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide has the following activities: antilipaemic, cardiant, vasotropic, antiarteriosolerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is custing serum cholsetorol in a subject (including a mammal such as a mouse, rat, rabbit; cow, sheep, pig, human, monkey, ape, dysbetalipoproteinements or atherosolerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein (LDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking polypeptide of the invention.

Sequence 14 AA;

February 14, 2007 16:01 Type: P Check: 8241 · .. Length: 14

GIRRFYGSIW RFLR

SEQUENCE 1.0 ADO34419 standard; peptide; 14 AA

12-AUG-2004 (first entry) *********

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 196.

vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetaliyoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL. apolipoprotein-E mimicking polypeptide;

Synthetic.

WO2004043403-A2.

27-MAY-2004

13-NOV-2003; 2003WO-US036268

13-NOV-2002; 2002US-0425821P %XGCCCCCCCCCCCCCCX

UABR-) UAB RES FOUND.

Datta Garber DW, Anantharamiah GM,

ö

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 196; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide acomposition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antiaking polypeptide has the following activities: antilipaemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is cueful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, appert changement or attentoresis; and for reducing the risk of dysbetalipoprotein-end or attentoresis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide of low-density lipoprotein (VLDL) to a cell and enhances degradation of LDL or cut animicking polypeptide of the invention.

Sequence 14 AA;

ADO34419 Length: 14 February 14, 2007 16:01 Type: P Check: 8198

GIRRYFSGLW RFIR

Ź !!AA_SEQUENCE 1.0 ID AD034227 standard; peptide; 18

ADO34227;

12-AUG-2004

Synthetic apolipoprotein-E mimicking related R18L linear peptide.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarreriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic

```
The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polymelecitide; a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal minched has the following activities: antilipaemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and ardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, chimpanzee or orangutan); for treating coronary artery disease, and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein. E mimicking of low-density lipoprotein (LDL) or very low density lipoprotein (VDL) to a cell and enhances degradation of LDL or very low-density lipoprotein-E mimicking coronary artery applied to the carpersents a synthetic apolipoprotein-E
                                                                                                                                                                                                                                                                              Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               polypeptide of the invention.
                                                                                                                                                                                                                                                                                                                                                         Claim 4; SEQ ID NO 4; 79pp; English
                                                                                                                                                                                                        Garber DW,
                                                                                          13-NOV-2003; 2003WO-US036268
                                                                                                                             13-NOV-2002; 2002US-0425821P
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  (first entry)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               GIRRFLGSIW RFIRAFVG
                                                                                                                                                                  (UABR-) UAB RES FOUND
                                                                                                                                                                                                                                           WPI; 2004-411629/38.
                                                                                                                                                                                                        Anantharamiah GM,
               WO2004043403-A2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                WO2004043403-A2.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Sequence 18 AA;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  12-AUG-2004
                                                    27-MAY-2004.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     27-MAY-2004
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Synthetic
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ADO34344;
```

ADO34227 Length: 18 February 14, 2007 16:01 Type: P Check: 2959

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 121. !!AA_SEQUENCE 1.0 ID ADO34344 standard; peptide; 18 AA.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol, coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; mycoardial infarction; stroke; embolus; angina, low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

13-NOV-2003; 2003WO-US036268.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence. ö Claim 4; SEQ ID NO 121; 79pp; English. Datta Garber DW, 13-NOV-2002; 2002US-0425821P. (UABR-) UAB RES FOUND. WPI; 2004-411629/38. Anantharamiah GM,

Datta G;

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid polypeptide. The invention further comprises an isolated nucleic acid a notypeptide. The invention further comprising polypeptide in a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polymelectide, a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an encolonal antibody that specifically binds to the synthetic an including polypeptide and a carrier; and an micking polypeptide has the following activities: antilipaemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide has the following activities: antilipaemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is cuseful for reducing serum cholesterol in a subject (including a mammal cuch as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, composition and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances blinding of low-density lipoprotein (ULD) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL, or very vy, we mimicking polypeptide of the invention.

Sequence 18 AA

February 14, 2007 16:01 Type: P Check: 2867 ADO34344 Length: 18

apolipoprotein-E mimicking polypeptide, antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; UDL; Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 149. 12-AUG-2004 (first entry) GIRRFYGSIW RFIRAFLG ADO34372;

13-NOV-2003; 2003WO-US036268 13-NOV-2002; 2002US-0425821P FOUND WO2004043403-A2. (UABR-) UAB RES 27-MAY-2004. Synthetic.

Datta G;

Garber DW,

WPI; 2004-411629/38. Anantharamiah GM,

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 149; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid coolypeptide. The invention further comprises an isolated nucleic acid cocomposition the synthetic apolipoprotein-E mimicking polypeptide, a vector.

(including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polymelectide, a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide as the following activities: antilippemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal c such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, chimpanzee or orangutan); for treating coronary artery disease, chimpanzee or paranterior apolipoprotein-E mimicking copypetide enhances binding of low-density an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E

Sequence 14 AA;

February 14, 2007 16:01 Type: P Check: 8211 Length: 14 AD034372

GFRRIYGSIW RFIR

!!AA_SEQUENCE 1.0 ID AD034333 standard; peptide; 18 AA. ADO34333;

12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 110.

apolipoprotein-E mimicking polypeptide, antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholestron! coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic.

WO2004043403-A2.

27-MAY-2004

13-NOV-2002; 2002US-0425821P.

13-NOV-2003; 2003WO-US036268

(UABR-) UAB RES FOUND.

Datta G; Anantharamiah GM, Garber DW,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis coronary artery disease, dysbetal: comprises an amino acid sequence,

Claim 4; SEQ ID NO 110; 79pp; English.

The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, (ancluding animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and ce manicking polypeptide encoding polynucleotide; a composition comprising comparising polypeptide encoding polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E cardiant, vasotropic, antiateriosolerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is cardiant, vasotropic, antiateriosolerotic, cerebroprotective, and antianginal in the synthetic apolipoprotein-E mimicking polypeptide is cardiant, vasotropic, antiaterion of constant and for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, consoratial infarction or stroke; for treating an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein-E mimicking polypeptide of the invention. invention relates to a novel synthetic apolipoprotein-E mimicking

Sequence 18 AA;

ADO34333 Length: 18 February 14, 2007 16:01 Type: P Check: 3007

GIRRILGSFW RFFRAIYG

!!AA SEQUENCE 1.0 ID ADO34339 standard; peptide; 18 AA.

AD034339;

12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 116.

vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL. apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant;

Synthetic.

WO2004043403-A2.

27-MAY-2004.

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND.

Datta G; Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 116; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide, a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polymucleotide, a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and

cardiant, vasotropic, antiatteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking density lipoprotein (UDL) or very low density lipoprotein (UDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking mimicking polypeptide of the invention. an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide has the following activities: antilipaemic, Sequence 18 AA; 8588858888888888888

February 14, 2007 16:01 Type: P Check: 2998 ADO34339 Length: 18

GLRRFIGSIW RFIRAFYG

!!AA_SEQUENCE 1.0 ID ADO34233 standard; peptide; 18 AA.

12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 10.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; UDL;

Synthetic

WO2004043403-A2.

27-MAY-2004

13-NOV-2003; 2003WO-US036268

13-NOV-2002; 2002US-0425821P.

FOUND (UABR-) UAB RES Garber DW, Datta G; Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 10; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polynucleotide; a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide has the following activities: antilipaemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,

chimpanzee or orangutan); for treating coronary artery disease, dysbetalipoproteinaemia or atherosclerosis, and for reducing the risk of myocardial infarction or stroke; for breaking an emborous in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein (LDL) or very low density, lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking polypeptide of the invention.

8888888888888

Sequence 18 AA;

February 14, 2007 16:01 Type: P ADO34233 Length: 18

GIRRFLGSIW RFIRAFYG

_SEQUENCE 1.0 _ADO34335 standard; peptide; 18 AA.

(first entry) 12-AUG-2004 Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 112.

vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL. apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant;

Synthetic..

WO2004043403-A2.

27-MAY-2004.

13-NOV-2003; 2003WO-US036268

13-NOV-2002; 2002US-0425821P

(UABR-) UAB RES FOUND.

ö Datta Garber DW, Anantharamiah GM,

API; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 112; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid composition of synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E comminicating polypeptide and a carrier; and the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and can monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide. The synthetic cardiant, vasocropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is cardiant, vasocropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal cach as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysbetalipoproteinaemia or atherosclerosis; and for reducing the subject; mycardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein (LDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or CULDL by a cell. This sequence represents a synthetic apolipoprotein-E

!!AA_SEQUENCE 1.0 ID ADO34244 standard; peptide; 18 AA.

(first entry)

12-AUG-2004

ADO34244;

```
The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid coolypeptide. The invention further comprises an isolated nucleic acid composition the synthetic apolipoprotein-E mimicking polypeptide a bost cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and can monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide has the following activities: antilipaemic, cardiant, vasokropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide has the following activities antilipaemic, cardiant, vasokropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide show the following coronary artery disease, chimpanzee or orangutan); for treating coronary artery disease, chimpanzee or orangutan); for treating coronary artery disease, chimpanzee or orangutan); for treating coronary artery disease, chapter and also for treating angina. The synthetic apolipoprotein-E mimicking copypeptide enhances blinding of low-density lipoprotein (VLDL) to a cell and enhances degradation of LDL or CVLDL by a cell. This sequence represents a synthetic apolipoprotein-E companie compa
                                                                                                                                                                                                                                                                                                                                                                                                                                              apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbeterlispoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.
                                                                                                         Type: P Check: 3019
                                                                                                                                                                                                                                                                                                                                                                                                  Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 11.
                                                                                                      ADO34335 Length: 18 February 14, 2007 16:01
mimicking polypeptide of the invention.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Datta G;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Claim 4; SEQ ID NO 11; 79pp; English.
                                                                                                                                                                                                                                      ADO34234 standard; peptide; 14 AA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Garber DW,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              13-NOV-2003; 2003WO-US036268.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  13-NOV-2002; 2002US-0425821P.
                                                                                                                                                                                                                                                                                                                                             12-AUG-2004 (first entry)
                                                                                                                                                        GFRRILGSIW RFIRAFYG
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  (UABR-) UAB RES FOUND.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              WPI; 2004-411629/38.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Anantharamiah GM,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       WO2004043403-A2.
                                                  Sequence 18 AA;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Sequence 14 AA;
                                                                                                                                                                                                        !! AA_SEQUENCE 1.0
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         27-MAY-2004.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Synthetic
                                                                                                                                                                                                                                                                                           ADO34234;
  SXC
```

ADO34234 Length: 14 February 14, 2007 16:01 Type: P Check: 8202

GIRRFYGSIW RFIR

```
The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide, a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic and carrier; and an monoclonal antibody that specifically binds to the synthetic and indicking polypeptide has the following activities: antilippenic, cardiant, vasotropic, antiarteriosclerotic, cereboprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is cardiant, vasotropic, antiarteriosclerotic, cereboprotective, and antianginal. The synthetic apolipoprotein-E mimicking a mammal crossing and for reducing serum cholesterol in a subject fincluding a mammal cuch as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, chimpanzee or orangutan) for treating coronary artery disease, compensation or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking copypeptide of low-density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E companies and contact and contact and contact and contact and enhances contact and enhances contact and enhances degradation of LDL or contact and enhances contact and enhan
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.
                                                                                                                                                                                                                                               vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dybbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
                                                                                                                                                                                                                  apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ADO34244 Length: 18 February 14, 2007 16:01 Type: P Check: 3136
                                                                                                                                                               Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 21.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Datta G;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Claim 4; SEQ ID NO 21; 79pp; English.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ADO34417 standard; peptide; 14 AA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Garber DW,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    13-NOV-2003; 2003WO-US036268.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       13-NOV-2002; 2002US-0425821P.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          12-AUG-2004 (first entry)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              GIRRFLGAIW RFIRSFYG
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             FOUND
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         WPI; 2004-411629/38.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Anantharamiah GM,
                                                                                                                                                                                                                                                                                                                                                                                                                                       WO2004043403-A2.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          (UABR-) UAB RES
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Sequence 18 AA;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                27-MAY-2004.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 !! AA_SEQUENCE 1.0
                                                                                                                                                                                                                                                                                                                                                                                    Synthetic.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       AD034417;
```

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 194.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic

WO2004043403-A2.

27-MAY-2004.

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND

Datta G; Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 194; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid comparing the synthetic apolipoprotein-E mimicking polypeptide, a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is untianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal cueful for reducing serum cholesterol in a subject (including a mammal subject infingance or orangutan); for treating coronary artery disease, dysbetalipoproteinaemia or atherosclerosis, and for reducing the risk of mycardial infarction or atherosclerosis, and cor reducing angina. The synthetic apolipoprotein-E minicking polypeptide enhances binding of low-density lipoprotein (UDL) or very low density lipoprotein-E minicking a synthetic apolipoprotein-E minicking coll and enhances degradation of LDL or very low included the synthetic apolipoprotein-E minicking entains a synthetic apolipoprotein-E mimicking polypeptide of the invention.

Sequence 14 AA;

ADO34417 Length: 14 February 14, 2007 16:01 Type: P Check: 8210

GIRRYFGSLW RFIR

ADO34337 standard; peptide; 18 AA. !! AA_SEQUENCE 1.0

AD034337;

12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 114.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiatrefiosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary arrery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina;

low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic.

WO2004043403-A2.

27-MAY-2004

13-NOV-2003; 2003WO-US036268.

(UABR-) UAB RES FOUND

Datta G; Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 114; 79pp; English.

cuch as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysbetalioproteinaemia or atherosclarosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject, and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein (LDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking polypeptide of the invention. The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide has the following activities; antilipaemic, cardiant, vasotropic, antiarteriosclerotic, carebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal

Sequence 18 AA;

AD034337 Length: 18 February 14, 2007 16:01 Type: P Check: 3019

GIRRFLGSFW RIIRAFYG

!!AA SEQUENCE 1.0 ID ADO34343 standard; peptide; 18 AA.

ADO34343;

(first entry) 12-AUG-2004

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 120.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; UDL;

Synthetic.

WO2004043403-A2.

27-MAY-2004

```
The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid cocomplaints as whether a synthetic apolipoprotein-E mimicking polypeptide, a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polymuleotide, a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and control antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E control and activities: antilipaemic, antiarteriogical activities: antilipaemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and mimicking polypeptide has the following activities: antilipaemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and cardiant, asouted as mouse, rat, rabbit, cow, sheep, pig, human, monkey, applyable to crangulant, in synthetic apolipoprotein-E mimicking of such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, and cor crangulant infarction or atherosclerosis, and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject, and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide of the invention.

Comminicking polypeptide of the invention.
                                                                                                                                                                                                                                                                Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.
                                                                                                                                                                      Datta G;
                                                                                                                                                                                                                                                                                                                                                                 Claim 4; SEQ ID NO 120; 79pp; English.
                                                                                                                                                                    Garber DW,
                    13-NOV-2003; 2003WO-US036268.
                                                                  13-NOV-2002; 2002US-0425821P.
                                                                                                                   UABR-) UAB RES FOUND
                                                                                                                                                                    Anantharamiah GM,
```

Sequence 18 AA;

ADO34343 Length: 18 February 14, 2007 16:01 Type: P Check: 2996

GIRRFLGSIY RFIRAFWG

!!AA_SEQUENCE 1.0 ID _ADO34342 standard; peptide; 18 AA.

(first entry) 12-AUG-2004

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 119.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbeterilipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic

WO2004043403-A2

27-MAY-2004

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND

Datta G; Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 119; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid coolypeptide. The invention further comprises an isolated nucleic acid concoling the synthetic apolipoprotein-E mimicking polypeptide, a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide to the synthetic apolipoprotein-E mimicking polypeptide as the following activities: antilipaemic, cardiant, vasotropic, antiarterios/clerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide as the following activities: antilipaemic, cardiant, vasotropic, antiarterios/clerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking a mammal for reducing serum cholesterol in a subject fincluding a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, convocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking coronary activity lipoprotein (VDD) to a cell and enhances degradation of LDL or cubby a cell. This sequence represents a synthetic apolipoprotein-E coronary artery disease, mimicking polypeptide of the invention.

Sequence 18 AA;

ADO34342 Length: 18 February 14, 2007 16:01 Type: P Check: 3061

GFRRFLGSFW RIIRAIYG

!!AA_SEQUENCE 1.0 ID AD034360 standard; peptide; 14 AA

ADO34360;

12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 137.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholestreol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic

WO2004043403-A2

27-MAY-2004

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND.

Datta G; Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 137; 79pp; English

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide, a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and mimicking polypeptide, The synthetic apolipoprotein-E cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal cost as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, comparated infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking copypatide enhances binding of low-density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E comparated and any any propertion.

Sequence 14 AA;

February 14, 2007 16:01 Type: P Check: 8274 ADO34360 Length: 14

RFLR GLRRFYGSLW

ADO34426 standard; peptide; 14 AA. !! AA_SEQUENCE 1.0

ADO34426;

12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 203.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholestreol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; LDL;

Synthetic

WO2004043403-A2.

27-MAY-2004.

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence. WPI; 2004-411629/38.

Datta G;

Garber DW,

Anantharamiah GM,

Claim 4; SEQ ID NO 203; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject

cc (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polynucleotide; a composition comprising ct he synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an emonoclonal antibody that specifically binds to the synthetic and monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide has the following activities: antilippemic, cardiant, vasotropic, antiarterios-clerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal cuseful for reducing earum cholesterol in a subject (including a mammal cuseful polypeptide and a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, comparation or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E, mimicking comparation of stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E, mimicking comparation of luble or vible by a cell. This sequence represents a synthetic apolipoprotein-E mimicking polypeptide of the invention.

Sequence 14 AA;

ADO34426 Length: 14 February 14, 2007 16:01 Type: P

GFRRLYSGIW RFIR

ADO34241 standard; peptide; 18 AA ! ! AA SEQUENCE 1.0

ADO34241;

12-AUG-2004

(first entry)

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density, lipoprotein; UDL. Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 18.

Synthetic.

WO2004043403-A2.

27-MAY-2004.

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND.

Datta G; Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 18; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polynucleotide; a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide has the following activities: antilipaemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and

antianginal. The synthetic apolipoprotein-E. mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysberalipoproteinaemia or atherosclerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein (LDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or windicking polypeptide of the invention.

Sequence 18 AA;

February 14, 2007 16:01 Type: P Check: 2998 ADO34241 Length: 18

GIRRFLSGIW RFIRAFYG

!!AA_SEQUENCE 1.0 ID ADO34418 standard; peptide; 14 AA.

ADO34418;

(first entry) 12-AUG-2004

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 195.

apolipoprotein-E mimicking polypeptide, antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholestron; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic.

WO2004043403-A2

27-MAY-2004

13-NOV-2003; 2003WO-US036268,

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND

Datta G; Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 195; 79pp; English.

such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanizee or orangutan); for treating coronary artery disease, dysbetaliopproteinsemia or atherososlerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide, a vector, a host cell, a recombinant cell or a transpendic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide has the following activities; antilipaemic, cardiant, vasotropic, antiarteriosoleroric, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal

polypeptide enhances binding of low-density lipoprotein (LDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking polypeptide of the invention. 8866688

Sequence 14

ADO34418 Length: 14 February 14, 2007 16:01 Type: P Check: 8228

GLRRYFGSIW RFLR

!!AA_SEQUENCE 1.0 ID ADO34350 standard; peptide; 18 AA.

ADO34350;

(first entry) 12-AUG-2004 Synthetic apolipoprotein-E mimicking peptide, SEQ ID

No 127.

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholesterol; coronary artery disease; dysbetalipoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

Synthetic.

WO2004043403-A2.

27-MAY-2004.

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND.

Datta G; Garber DW, Anantharamiah GM,

WPI; 2004-411629/38.

Synthetic apolipoprotein-B mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 127; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polymbolectide; a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide is cardiant, vasotropic, antiarteriosclerotic, carebroprotective, and antiaginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, oww, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treading coronary artery disease, chimpanzee or orangutan); for treading coronary artery disease, chimpanzee or orangutan) or atterosclerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking bodypeptide enhances binding of low-density lipoprotein (ULDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking polypeptide of the invention.

Sequence 18 AA;

ADX96509;

Type: P Check: 3064 ADO34350 Length: 18 February 14, 2007 16:01

1 GLRRFIGSLW RFLRAFYG

ilAA SEQUENCE 1.0 ID ADO34378 standard; peptide; 14 AA. ADO34378; 12-AUG-2004 (first entry)

apolipoprotein-E mimicking polypeptide; antilipaemic; cardiant; vasotropic; antiarteriosclerotic; cerebroprotective; antianginal; serum cholestreol; coronary artery disease; dysbeterilpoproteinaemia; atherosclerosis; myocardial infarction; stroke; embolus; angina; low-density lipoprotein; LDL; very low density lipoprotein; UDL; Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 155.

WO2004043403-A2.

27-MAY-2004

13-NOV-2003; 2003WO-US036268

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND

Datta G; Anantharamiah GM, Garber DW,

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

Claim 4; SEQ ID NO 155; 79pp; English.

The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid polypeptide. The invention further comprises an isolated nucleic acid ancomplaint to synthetic apolipoprotein-E mimicking polypeptide, a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide as the following activities: antilippemic, cardiant, vasotropic, antiareriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, and also for treating angina. The synthetic apolipoprotein-E mimicking of low-density lipoprotein (VLDL) to a cell and enhances binding of low-density lipoprotein-E mimicking polypeptide of the invention.

Sequence 14 AA;

Type: P Check: 8241 February 14, 2007 16:01 ADO34378 Length: 14

GIRRFYGSIW RFLR

||AA_SEQUENCE 1.0 |ID ADX96509 standard; protein; 671 AA.

plant protectant; plant growth regulant; gene therapy; plant; recombinant DNA construct; physical array; plant breeding marker; cold tolerance; heat tolerance; drought tolerance; herbicide tolerance; extreme osmotic condition; pathogen tolerance; pest tolerance; growth rate; cell cycle pathway; disease resistance; galactomannan production; lignin production; plant growth regulator; yield; plant growth; plant development; seed oil; protein yield; Cao Y; Tabaska JE, Plant full length insert polypeptide seqid 59173. Screen SE, 06-MAY-1999; 99US-00304517. 28-APR-2003; 2003US-00425114 Kovalic DK, (first entry) ZHOU Y. KOVALIC D K. SCREEN S E. WPI; 2004-180133/17. TABASKA J E. Zhou Y, US2004034888-A1 protein content CAO Y. 21-APR-2005 Unidentified. 19-FEB-2004. (TABA/) (CAOY/) (rin1/) (ZHOU/) (KOVA/) SCRE/) Liu J,

New recombinant DNA construct, useful for improving plant tolerance to cold, heat, drought, herbicides, extreme osmotic conditions, pathogens or pests, for conferring increased resistance to plant disease, or for improving yield.

Claim 1; SEQ ID NO 59173; 15pp; English.

The invention describes a recombinant DNA construct comprising a polynucleotide consisting of a sequence encoding an amino acid sequence polynucleotide consisting of a sequence encoding an amino acid sequence available in electronic form from the US patent office at the sequence. The sequence. The US patent of Fice at the polynucleotide of the invention are also useful in physical arrays of molecules and as plant breeding markers. The recombinant DNA construct is useful for improving plant tolerance to cold, heat, droublt, hearbicides, extreme osmotic conditions, pathogens or pests, for manipulating growth rate in plant cells by modification of the cell cycle pathway, for conferring increased resistance to plant disease, for producing galactomannan, recombination in plants, for increasing the rate of homologous recombination in plants, for improving yield by modification of photosynthesis or carbohydrate, nitrogen or phosphorus use and/or uptake or by providing improved plant growth and development under at least one carries condition or for modifying seed oil or protein yield and/or content. This is the amino acid sequence of a plant full length insert polypeptide that can be used in the recombinant DNA construct of the

Sequence 671 AA;

ADX96509 Length: 671 February 14, 2007 16:01 Type: P Check: 8299

- DPEEPPHPRR ARSGPARSPH APDPPGLATT GRPLPAPPRA Н
- PAHLAVLRRD HAALRRLVAA LPRLPRAGEV ATEEESIAGE AVADAVSAVV 21
- DRRDVPRRET PLHLAVRLRD PVAADVLMSA GADWSLQNAD GWSALQEAVC 101

```
DQTFLFLGDG
TREEAIATII ARHYQPLAWA KWCRRLPRIL ASISRIRDFY MEITFHFESS
                                                                                                                               KTNMYRPGID VTQAELVPHL NWRRQERAEA VGQWKAKVYD MLNVLVTVKS
                                                                                                                                                                            RRVPGAMTDE ELFAMDGEEK NGRGAELDAE LDEVLTAEER KOLDSALRMG
                                                                                                                                                                                                                        DEGDTGAGHM DEHAAAKDKK GWFGWGGKKG AKGDDKPSKM
                                                                                                                                                                                                                                                                   GSKDETSDPG KQKEKGSGKK KKGGSPAESL KHESEYKKGL RPVLWLTPDF
                                                                                                                                                                                                                                                                                                                PLKTDELIPL LDVLANKVKA VRRLRELLTT KLPTGTFPVK IAIPIVPTIR
                                                                                                                                                                                                                                                                                                                                                          VIVTFTKFES LOPLDEFATP PSSPTQFQDA KTKESEGSGS WYSWVKGGRG
                                                                                                                                                                                                                                                                                                                                                                                                         TEKKRRMKAK KAKSRRGPAR
                                        VIPFISRIAP SDTYRIWKRG AALRADMTLA GFDGFRIQRS
                                                                                       LHPGSLIVLA HKDKEITDAL EGAGVQPTES
                                                                                                                                                                                                                                                                                                                                                                                                       TOSSDSGDSR SWKDEVDPFH IPSDYTWVDA
                                                                                                                                                                                                                                                                                                                                                                                                                                                    KQSSKNTAEG AHRPMMDGFE
                                                                                    ARPEDAGGKE
                                                                                                                                                                                                                      NNEEESEORC
                                        201
                                                                                    251
                                                                                                                               301
                                                                                                                                                                         351
                                                                                                                                                                                                                                                                                                                                                          551
                                                                                                                                                                                                                                                                                                                                                                                                       601
                                                                                                                                                                                                                                                                                                                                                                                                                                                      651
                                                                                                                                                                                                                        401
                                                                                                                                                                                                                                                                451
                                                                                                                                                                                                                                                                                                             501
```

SEQUENCE 1.0 ADY07006 standard; protein; 646 AA. : A

ADY07006;

21-APR-2005 (first entry)

Plant full length insert polypeptide seqid 62821.

recombinant DNA construct; physical array; plant breeding marker; cold tolerance; heat tolerance; drought tolerance; herbicide tolerance; extreme osmotic condition; pathogen tolerance; pest tolerance; growth rate; cell cycle pathway; disease resistance; galactomannan production; lignin production; plant growth regulator; yield; plant growth; plant development; seed oil; protein yield; plant protectant; plant growth regulant; gene therapy; plant; protein content

Unidentified

US2004034888-A1

19-FEB-2004

28-APR-2003; 2003US-00425114.

06-MAY-1999; 99US-00304517, 05-NOV-2001; 2001US-00985678.

KOVALIC D K. SCREEN S E. TABASKA J E. CAO Y. LIU J. ZHOU Y. (/rnin) (KOVA/) SCRE/

(TABA/) (CAOY/)

Cao Y; Tabaska JE, Screen SE, Kovalic DK, Zhou Y, iu J,

WPI; 2004-180133/17.

ö New recombinant DNA construct, useful for improving plant tolerance to cold, heat, drought, herbicides, extreme osmotic conditions, pathogens pests, for conferring increased resistance to plant disease, or for improving yield.

Claim 1; SEQ ID NO 62821; 15pp; English.

The invention describes a recombinant DNA construct comprising a polynucleotide consisting of a sequence encoding an amino acid sequence available in electronic form from the US patent office at ftp.seqdata.uspto.gov/sequence.html?DocID:2004034888. The polynucleotide

of the invention are also useful in physical arrays of molecules and as land the theoreting markers. The recombinant DNA construct is useful for improving plant tolerance to cold, heat, drought, herbicides, extreme osmotic conditions, pathogens or pests, for manipulating growth rate in plant cells by modification of the cell cycle pethay, for conferring increased resistance to plant disease, for increasing the rate of homologous light or plant growth regulators, for increasing the rate of homologous photosynthesis or carbohydrate, nitrogen or phosphorus use and/or uptake or by providing improved plant growth and development under at least one stress condition or for modifying seed oil or protein yield and/or content. This is the amino acid sequence of a plant full length insert polypeptide that can be used in the recombinant DNA construct of the invention. 8888888888888888888888888

Sequence 646 AA;

Type: P Check: 750 February 14, 2007 16:01 ADY07006 Length: 646

- PSYDRPAGPA PPPAMDDVSK YAHSPAHLAV LRRDHAALRR LVAALPRLPR
- AGEVATEEES VAGEAVADAV SAVIDRRDVP RRETPLHLAV RLRDPVAADI 21
- LMSAGADWSL QNADGWSALQ EAVCTREEAI ATIIARHYQP LAWAKWCRRL 101
- MTLAGFDGFR IQRSDQTFLF LGDGARPEDA GGKELHSGSL IVLAHKDKEI RDFYMEISFH FESSVIPFIG RIAPSDTYRI PRILASISRI 151 201
- TDALEGAGVQ PTESEVAHEV ALMSKTNMYR PGIDVTQAEL VPHLNWRRQE 251
- RTEAVGOWKA KVYDMLNVLV TVKSRRVPGA MTDEELFAMD GEEKNGRGAE 301
- AEERKOLDSA LRMGNNEEES LDAELDEVLT
- 351
- AESVKHESEY KKGLRPVLWL TPDFPLKTDE LIPLLDVLAN KVKAIRRLRE 451

KDKKGWFGWG AKKGAKGDDK PSKVGSKDET SDPGKQKEKG SGKKKKGGSS

401

- LLTTKLPTGT FPVKIAIPIV PTIRVIITFT KFEELQPLDE FATPPSSPTQ 501
- **DPFHIPSDYT** FQDAKAKEPE GSGSWYSWVK GGRGTQSGDS GDGRNWKDEV 551

WVDATEKKRR MKAKKAKSRR TTARKQSSKN TSSEGGHRPM MDGFEE

601